Cite
Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
MLA
Pei, Fei, et al. “Octamer-Binding Transcription Factor 4-Positive Circulating Tumor Cell Predicts Worse Treatment Response and Survival in Advanced Cholangiocarcinoma Patients Who Receive Immune Checkpoint Inhibitors Treatment.” World Journal of Surgical Oncology, vol. 22, no. 1, Apr. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12957-024-03369-7.
APA
Pei, F., Tao, Z., Lu, Q., Fang, T., & Peng, S. (2024). Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment. World Journal of Surgical Oncology, 22(1), 1–10. https://doi.org/10.1186/s12957-024-03369-7
Chicago
Pei, Fei, Zhen Tao, Qi Lu, Tao Fang, and Shasha Peng. 2024. “Octamer-Binding Transcription Factor 4-Positive Circulating Tumor Cell Predicts Worse Treatment Response and Survival in Advanced Cholangiocarcinoma Patients Who Receive Immune Checkpoint Inhibitors Treatment.” World Journal of Surgical Oncology 22 (1): 1–10. doi:10.1186/s12957-024-03369-7.